Compare · IONS vs XCUR
IONS vs XCUR
Side-by-side comparison of Ionis Pharmaceuticals Inc. (IONS) and Exicure Inc. (XCUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IONS and XCUR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- IONS is the larger of the two at $4.84B, about 684.6x XCUR ($7.1M).
- IONS has been more active in the news (7 items in the past 4 weeks vs 4 for XCUR).
- IONS has more recent analyst coverage (25 ratings vs 2 for XCUR).
- Company
- Ionis Pharmaceuticals Inc.
- Exicure Inc.
- Price
- -
- -
- Market cap
- $4.84B
- $7.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 4
- Recent ratings
- 25
- 2
Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Exicure Inc.
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
Latest IONS
- Director Hayden Michael R bought $148,200 worth of shares (5,000 units at $29.64) (SEC Form 4)
- Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
- Ionis to present at upcoming investor conferences
- SEC Form 10-Q filed by Ionis Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ionis reports third quarter 2026 financial results and highlights progress on key programs
- Ionis to hold third quarter 2026 financial results webcast
- SEC Form 8-K filed by Ionis Pharmaceuticals Inc.
- Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
- Ionis ranked #1 on Science’s Top Employers list
Latest XCUR
- SEC Form DEF 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
- SEC Form PRE 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
- SEC Form 10-Q filed by Exicure Inc.
- Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
- Large owner Exicure Hitron Inc. acquired $2,804,738 worth of Common (623,275 units at $4.50), increasing direct ownership by 39% to 2,222,224 units (SEC Form 4)
- Exicure Inc. filed SEC Form 8-K: Leadership Update